Filaria control and elimination: diagnostic, monitoring and surveillance needs.
Gold standard diagnosis using blood films or skin snips has dimished relevance as mass drug distribution programmes for control of filaria infections expand. The view of 'diagnosis' and its relevance at the individual level has changed, as it has been recognised that the spectrum of programmatic processes (mapping, mass drug interventions, monitoring and evaluation, and surveillance) require different approaches as different questions are asked at each stage. The feasibility and relevance of skin biopsy or blood film examination is challenged when mass drug distribution seeks to treat all eligibles in communities. The need to expand programmes rapidly by identifying the highest risk communities has seen the development of rapid assessment methods, such as rapid epidemiological mapping of onchocerciasis (REMO) and rapid epidemiological assessment (REA) for onchocerciasis, immunochromatographic test (ICT)-based mapping for lymphatic filariasis (LF), and Rapid Assessment Procedure for Loiasis (RAPLOA) for Loa, to reduce the risk of serious adverse events and to guide projects in high-risk communities. As programmes reduce the prevalence through mass drug distribution, more sensitive techniques are required to define endpoints, for LF in particular where the programmatic goal is elimination; for onchocerciasis, sensitive surveillance tools are required particularly in those areas where such risks of recrudescence are high. Whilst much progress has been made in the development and deployment of rapid methods, there are still specific needs for antigen detection in onchocerciasis, whilst standardisation of a panel of tools for LF will allow the definition of endpoint parameters so that countries can decide when mass drug administration (MDA) can be stopped and have a sensitive post-MDA surveillance system.
Molyneux
David H
DH
Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. david.molyneux@liv.ac.uk
D000349:Africa / Q000453:epidemiology; D000818:Animals; D017178:Brugia malayi / Q000302:isolation & purification; D004320:Dracunculiasis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D004605:Elephantiasis, Filarial / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D005368:Filariasis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D005369:Filaricides / Q000627:therapeutic use*; D006801:Humans; D008117:Loa / Q000302:isolation & purification; D008118:Loiasis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D009855:Onchocerciasis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D000091402:Prohibitins; D014958:Wuchereria bancrofti / Q000302:isolation & purification
D005369:Filaricides; C000717331:PHB2 protein, human; D000091402:Prohibitins